Tecvayli + Talvey Reduced the Risk of Disease Progression or Death by 89% and the Risk of Death by 62% in Earlier-Line Relapsed/refractory Multiple Myeloma
July 24, 2026
July 24, 2026
RARITAN, New Jersey, July 24 -- Johnson and Johnson Innovative Medicine issued the following news release on July 23, 2026:
* * *
TECVAYLI(R) + TALVEY(R) reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
- Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma
* * *
TECVAYLI(R) + TALVEY(R) reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
- Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma